Antengene Corporation Limited today announced that China National Medical Products Administration (NMPA) has approved the Phase I study of ATG-101 (the PROBE-CN study) for the treatment of advanced/ metastatic solid tumors and B-cell non-Hodgkin lymphoma (B-NHL). ATG-101 is a novel bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce…
ສິ່ງທີ່ຄວນເອົາໄປຈາກບົດຄວາມນີ້:
- ATG-101 is a novel bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce….
- ບໍລິສັດ Antengene Corporation Limited ປະກາດໃນມື້ນີ້ວ່າການຄຸ້ມຄອງຜະລິດຕະພັນທາງການແພດແຫ່ງຊາດຈີນ (NMPA) ໄດ້ອະນຸມັດການສຶກສາໄລຍະ I ຂອງ ATG-101 (ການສຶກສາ PROBE-CN) ສໍາລັບການປິ່ນປົວເນື້ອງອກແຂງແບບພິເສດ / metastatic ແລະ lymphoma ທີ່ບໍ່ແມ່ນ Hodgkin ຈຸລັງ B (B. -NHL).
- ການສະໝັກໃຊ້ແມ່ນບໍ່ເສຍຄ່າ.